
Nido Bio: Developing precision medicines for severe neurological diseases using advanced neuroscience.
Nido Biosciences is a clinical-stage company founded with the mission to develop precision medicines for severe neurological diseases. Utilizing the latest advances in neuroscience and human genetics, Nido Bio aims to create treatments that address the fundamental biology of these conditions and restore healthy cell function. Their market focus is on severe neurological illnesses, leveraging cutting-edge scientific research to push the boundaries of what is possible in drug discovery and development.
The company is supported by a team of dedicated drug development and neuroscience experts, along with world-class scientific advisors and leading industry investors. Nido Biosciences has achieved significant milestones in translating neuroscience breakthroughs into potential treatments, making a notable impact in the field of precision medicine for neurological diseases. Their innovative approach has positioned them as a key player in the biopharmaceutical industry, driving forward the development of targeted therapies for complex neurological conditions.

Neuron23

Nura Bio
nurabio.com

Neurogene
neurogene.com

Nested Therapeutics
nestedtx.com

Empyrean Neuroscience
empyrean.bio

Rapport Therapeutics

Novoron Bioscience
novoron.com

Praxis Precision Medicines

Precision IBD

Niche Biomedical

Actio Biosciences
actiobio.com
NeuroBionics

HI-Bio
hibio.com

Reservoir Neuroscience
reservoirneuro.com

Aprinoia Therapeutics
aprinoia.com
Companies similar to Nido Biosciences include Neuron23, Nura Bio, Neurogene and Nested Therapeutics.
Nido Biosciences was founded in 2018.
Nido Biosciences' headquarters is located in Boston, MA, US.
Nido Biosciences' most recent funding round was for $86.6M (USD) in May 2023.
As of May 15, 2023, Nido Biosciences has raised a total of $109M (USD).
Nido Biosciences has 30 employees as of Feb 5, 2024.